Acute myeloid leukaemia vaccine - AVAX Technologies
Alternative Names: Acute myelogenous leukaemia vaccine - AVAX Technologies; L-Vax; Leukaemia vaccine - AVAX TechnologiesLatest Information Update: 25 Sep 2021
At a glance
- Originator AVAX Technologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 18 May 2000 Phase-II clinical trials for Acute myeloid leukaemia in USA (Intradermal)